Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.61 |
| ▸ | CYP26A1 | O43174 | 10/20 | 0.57 |
| ▸ | RARB | P10826 | 7/20 | 0.55 |
| ▸ | RARG | P13631 | 7/20 | 0.55 |
| ▸ | RARA | P10276 | 6/20 | 0.55 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 3/20 | 0.50 |
| ▸ | RXRB | P28702 | 3/20 | 0.50 |
| ▸ | RXRG | P48443 | 3/20 | 0.50 |
| ▸ | CYP26B1 | Q9NR63 | 4/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881850 | 0.89 | RARB (0.71) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL7709220 | 0.82 | CYP3A4 (0.65) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL8005377 | 0.81 | RXRA (0.74) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL6881535 | 0.80 | CYP3A4 (0.55) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL6879098 | 0.80 | CYP3A4 (0.55) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL2788640 | 0.79 | CYP3A4 (0.70) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL7715161 | 0.79 | CYP3A4 (0.54) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL6871521 | 0.79 | CYP3A4 (0.54) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL8681604 | 0.78 | CYP3A4 (0.53) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL6880830 | 0.78 | CYP3A4 (0.53) | CYP3A4CYP26A1RARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100583-A1 | Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them | GALDERMA RESEARCH & DEVELOPMENT | 2003-05-29 | — | — | US | claimed |
| EP-0952975-B1 | BI-AROMATIC COMPOUNDS BOUND BY A HETEROETHYNYLENE RADICAL AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2002-07-10 | — | — | EP | claimed |
| US-20010056105-A1 | Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them | GALDERAMA RESEARCH & DEVELOPMENT. | 2001-12-27 | — | — | US | claimed |
| US-6201019-B1 | ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-03-13 | — | — | US | claimed |
| US-6818666-B2 | FOR EXAMPLE, METHYL 4-(5,5,8,8,-TETRAMETHYL-5,6,7,8-TETRAHYDRO-2 -NAPHTHYLSULPHANYLETHYNYL)BENZOATE; USE IN HUMAN OR VETERINARY MEDICINE OR COSMETIC COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2004-11-16 | — | — | US | disclosed |
| US-20030100583-A1 | Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them | GALDERMA RESEARCH & DEVELOPMENT | 2003-05-29 | — | — | US | disclosed |
| US-6441010-B2 | USEFUL AS COSMETIC FOR HAIR AND BODY HYGIENE, AND FOR TREATMENT OF DERMATOLOGICAL COMPLAINTS, WITH AN INFLAMMATORY AND/OR IMMUNOALLERGIC COMPONENT OF RHEUMATIC OR RESPIRATORY TYPE, CARDIVASCULAR AND OPTHALMOGICAL DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-08-27 | — | — | US | disclosed |
| US-20010056105-A1 | Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them | GALDERAMA RESEARCH & DEVELOPMENT. | 2001-12-27 | — | — | US | disclosed |
| US-6201019-B1 | ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056105-A1 | Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them | TYR, KRT18, SCO2 | CYP3A4 513/4885CYP26A1 319/4885RARB 680/4885 |
| US-20030100583-A1 | Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them | TYR, AHR, CYP2C19 | CYP3A4 25/4885CYP26A1 192/4885RARB 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.